Zatońska K, Psikus P, Basiak-Rasała A et al (2021) Obesity and chosen non-communicable diseases in pure poland cohort study. Int J Environ Res Public Health 18(5):2701

Article  PubMed  PubMed Central  Google Scholar 

Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J (2022) Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health 7(9):e009773

Article  PubMed  PubMed Central  Google Scholar 

https://www.who.int/news/item/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity. Accessed 3 June 2023

Chang SH, Stoll CR, Song J et al (2014) The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg 149:275–287

Article  PubMed  PubMed Central  Google Scholar 

Sjöström L, Peltonen M, Jacobson P et al (2014) Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311:2297–2304

Article  PubMed  Google Scholar 

Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J (2017) Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA 318(15):1460–1470

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrèges JP, Lindegaard ML, Jensen CB, Atkin SL (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care 39(2):231–241

Article  CAS  PubMed  Google Scholar 

Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D (2020) Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. J Obesity 28(6):1050–1061

Article  CAS  Google Scholar 

Garvey WT, Batterhazm RL, Bhatta M, Buscemi S et al (2022) Two years effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28(10):2083–2091

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chao AM, Tronieri JS, Amaro A, Wadden TA (2023) Semaglutide for the treatment of obesity. Trends Cardiovasc Med 33(3):159–166

Article  CAS  PubMed  Google Scholar 

Lepsen EW, Lundgren JR, Hartmann B et al (2015) GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab 100(8):2909–2917

Article  Google Scholar 

Gautier JF, Choukem SP, Girard J (2008) Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 34(Suppl 2):S65-72

Article  CAS  PubMed  Google Scholar 

Hygum K, Harsløf T, Langdahl B, Starup-Linde J (2019) Glucagon-like peptide-1 receptor agonists and fracture risk—limitations to current knowledge. Osteoporos Int 30(8):1709–1710

Article  CAS  PubMed  Google Scholar 

Thomas MK, Nikooienejad A, Bray R et al (2021) Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab 106(2):388–396

Article  PubMed  Google Scholar 

Jastreboff AM, Kaplan LM, Frías JP et al (2023) Triple–hormone-receptor agonist retatrutide for obesity—A phase 2 trial. N Engl J Med 389:514–526

Article  CAS  PubMed  Google Scholar 

Gadde KM, Martin CK, Berthoud HR, Heymsfield SB (2018) Obesity: pathophysiology and management. J Am Coll Cardiol 71(1):69–84

Article  PubMed  PubMed Central  Google Scholar 

Pasquali R, Casanueva F, Haluzik M et al (2020) European society of endocrinology clinical practice guideline: endocrine work-up in obesity. Eur J Endocrinol 182(1):G1–G32

Article  CAS  PubMed  Google Scholar 

Ryan DH, Lingvay I, Colhoum HM, Denfield J et al (2020) Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (Select) rationale and design. Am J Heart 229:61–69

Article  Google Scholar 

Kadawaki T, Isendahl JK, Khalid U, Lee SW et al (2022) Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(22)00008-0

Article  Google Scholar 

Rubino DM, Grenway FL, Khalid O, Oeil PM et al (2022) Effect of weekly subcutaneous Semaglutide vs daily Liraglutide on body weight in adults with overweight or obesity without diabetes. The step 8 randomized clinical study. JAMA 327(2):138–150

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weghuber D, Barett T, Barrientos-Pérez M, Gies I et al (2022) Once-weekly semaglutide in adolescents with obesity. N Engl J Med. https://doi.org/10.1056/NEJMoa2208601

Article  PubMed  PubMed Central  Google Scholar 

Schlienger JL, Monnier L (2023) Co-agonistes des récepteurs du GIP et du GLP-1: une innovation thérapeutique majeure dans le traitement du diabète de type 2. Med Mal Metab 17:49–57

Google Scholar 

Enebo LB, Berthelsen KK, Kankam M, Lund MT et al (2022) Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 397:1736–1748

Article  Google Scholar 

Lau DCW, Erichsen L, Francisco AM, Satylganova A et al (2022) Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. https://doi.org/10.1016/S0140-6736(21)01751-7

Article  PubMed  PubMed Central  Google Scholar 

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205–216

Article  CAS  PubMed  Google Scholar 

Lespessailles E, Paccou J, Javier RM et al (2010) GRIO scientific committee. obesity, bariatric surgery, and fractures. J Clin Endocrinol Metab 104:4756–4768

Article  Google Scholar 

Paccou J, Caiazzo R, Lespessailles E, Cortet B (2022) Bariatric surgery and osteoporosis. Calcif Tissue Int 110:576–591

Article  CAS  PubMed  Google Scholar 

Jensen VFH, Mølck AM, Dalgaard M, McGuigan FE, Akesson KE (2021) Changes in bone mass associated with obesity and weight loss in humans: applicability of animal models. Bone 145:115781

Article  PubMed  Google Scholar 

Papageorgiou M, Biver E (2023) Bone consequences of intentional weight loss in overweight or obese patients. Rev Med Suisse 19:756–760

PubMed  Google Scholar 

Armamento-Villareal R, Aguirre L, Waters DL, Napoli N, Qualls C, Villareal DT (2020) Effect of aerobic or resistance exercise, or both, on bone mineral density and bone metabolism in obese older adults while dieting: a randomized controlled trial. J Bone Miner Res 35:430–439

Article  CAS  PubMed  Google Scholar 

Pines A (2012) Weight loss, weight regain and bone health. Climacteric 15:317–319

Article  PubMed  Google Scholar 

Zibellini J et al (2015) Does diet-induced weight loss lead to bone loss in overweight or obese adults? A systematic review and meta-analysis of clinical trials. J Bone Miner Res. https://doi.org/10.1002/jbmr.2564

Article  PubMed  Google Scholar 

Uusi-Rasi K et al (2010) Three-month weight reduction does not compromise bone strength in obese premenopausal women. Bone. https://doi.org/10.1016/j.bone.2009.10.013

Article  PubMed  Google Scholar 

Uusi-Rasi K et al (2009) Influence of weight reduction on muscle performance and bone mass, structure and metabolism in obese premenopausal women. J Musculoskelet Neuronal Interact 9:72–80

CAS  PubMed  Google Scholar 

Villareal DT, Shah K, Banks MR, Sinacore DR, Klein S (2008) Effect of weight loss and exercise therapy on bone metabolism and mass in obese older adults: a one-year randomized controlled trial. J Clin Endoc Metab. https://doi.org/10.1210/jc.2007-1473

Article  Google Scholar 

Papageorgiou M, Kerschan-Schindl K, Sathyapalan T, Pietschmann P (2020) Is weight loss harmful for skeletal health in obese older adults? Gerontology 66(1):2–14

Article  PubMed  Google Scholar 

Lv QB et al (2015) The relationship between weight change and risk of hip fracture: meta-analysis of prospective studies. Sci Rep 5:16030

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ensrud KE, Ewing SK, Stone KL et al (2003) Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. J Am Geriatr Soc 51(12):1740–1747

Article  PubMed  Google Scholar 

Compston JE, Wyman A, FitzGerald G et al (2016) Increase in fracture risk following unintentional weight loss in postmenopausal women: the global longitudinal study of osteoporosis in women. J Bone Miner Res 31(7):1466–1472

Article  PubMed  Google Scholar